...Good morning. I am Todd Brady, President and Chief Executive Officer of Aldeyra Therapeutics. I want to begin by thanking all of you for joining what is our first Investor Roundtable at Aldeyra. We are genuinely appreciative of your interest in Aldeyra and seek to maintain an active dialogue with investors as we continue to pursue our mission of discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases. The purpose of this Investor Roundtable is to answer questions raised primarily by retail investors, effectively giving investors with whom we may not have regular dialogue the chance to approach our data management directly and given that our financial statements other than cash balance and projected operational runway are not, in our opinion, relevant to our business from an investment standpoint at this time. We do not hold quarterly financial calls. We do, however, attempt to maintain a robust schedule of calls and presentations, most of...
